About the Editors
Adrian L Harris
Adrian Harris is the Cancer Research UK Professor of Medical Oncology at the University of Oxford and directs the Cancer Research UK Molecular Oncology Laboratories at the Weatherall Institute of Molecular Medicine (WIMM). He is a Consultant Medical Oncologist and a Professorial Fellow of St Hugh's College Oxford. He is Chairman of the CRUK Oxford Cancer Centre and joint lead of the Cancer theme of the Comprehensive Biomedical Research Centre in Oxford. He is a Senior Investigator in the National Institute of Health Research and a Fellow of the Academy of Medical Sciences. He is a 'Highly Cited Researcher 2014' ranking among the top 1% most cited for their subject field and year of publication-between 2002 and 2012.
He trained in Medicine and Biochemistry at Liverpool University, did a DPhil at Oxford University then trained at the Royal Marsden Hospital in Medical Oncology. He was appointed Professor of Clinical Oncology at Newcastle-upon-Tyne in 1982. Since 1988 he has been the Professor of Medical Oncology at Oxford University. His major laboratory interests involve the role of hypoxia in breast tumour biology, and tumour angiogenesis, the metabolic response to hypoxia, microRNAs induced by hypoxia and hypoxia-induced cell death. He has conducted many predictive and prognostic studies and early exploratory phase trials in new drug development and molecular pathology to translate laboratory findings to clinical relevance and development of new agents.
Margaret Ashcroft (Cellular and Molecular Biology)
Prof. Margaret Ashcroft graduated with honours in Pharmacology and received a PhD in Molecular Cell Biology from the University of Bristol. She worked under the supervision of David Kaplan and subsequently Karen Vousden having obtained a prestigious Human Frontiers Fellowship, at the National Cancer Institute (U.S.), where she studied survival and cell death signalling mechanisms in cancer. From 2001, she joined the Institute of Cancer Research, London, where she made key discoveries in hypoxia signalling in cancer, and was one of the first groups to develop a small molecule hypoxia screen and identify novel small molecule agents targeting hypoxia signalling. In 2008, she was recruited to University College London to set up and head the Centre for Cell Signalling and Molecular Genetics, where she continued to make seminal discoveries in hypoxia biology, and progress her novel small molecule agents pre-clinically. In 2014, she was elected to the Professorship of Hypoxia Signalling and Cell Biology at the University of Cambridge, where she continues to lead a multidisciplinary team of biologists and chemists, thus integrating her basic and translational research efforts. She was elected as a Fellow of the Royal Society of Biology (FRSB) in 2011 and was awarded an Honorary Membership of the Royal College of Radiologists (MRCR) in 2015 for her contributions to oncology.
Angela Cox (Genetics and Genomics)
Angela Cox is Professor of Cancer Genetic Epidemiology at the University of Sheffield, UK, where she is an executive member of the Sheffield Experimental Cancer Medicine Centre (ECMC) and the Sheffield Institute for Nucleic Acids (SInFoNiA), and Deputy Head of the Department of Oncology and Metabolism. She obtained BA in Natural Sciences (genetics) from the University of Cambridge and PhD in molecular biology from University College London, and has been working in the area of genetic epidemiology and genomics of cancer since 2000.
Professor Cox’s research is focussed on inherited cancer susceptibility variants and circulating tumour DNA biomarkers. She collaborates in a number of international genetics consortia including BCAC, Interlymph, and ILCCO. She is interested in the mathematical modelling of the functional effects of inherited variants, and the development of new statistical genomics approaches. The Cox lab is a collecting centre for the Breast Cancer Now Tissue Bank, specialising in longitudinal blood sampling for circulating tumour DNA analysis, and she is exploring predictive and prognostic circulating DNA markers in a number of common cancers.
Jeff Evans (Clinical studies)
Jeff Evans is a Group Leader (Translational Cancer Therapeutics Laboratory) at the CR-UK Beatson Institute, Glasgow, Professor of Translational Cancer Research and Director of the Institute of Cancer Sciences, University of Glasgow, and Honorary Consultant in Medical Oncology at the Beatson West of Scotland Cancer Centre, Glasgow, and Lead of the Glasgow Experimental Cancer Medicine Centre (ECMC).
His research interests are in the pre-clinical and clinical development of novel anti-cancer agents, and his clinical interests are in Upper GI Cancers and Melanoma, and he leads the Phase I clinical trials and drug development team in Glasgow. He is a member of the NCRN Upper GI Cancer Pancreatic Cancer and Gastro-Oesophageal Cancer sub-groups, member of the ECMC - Industry Combinations Alliance Joint Steering Committee, member of CR-UK's Clinical Experts Review Panel, and former member of Cancer Research UK's New Agents Committee. He is co-editor of the clinical research section of the British Journal of Cancer.
Suzanne Fuqua (Translational Therapeutics)
Suzanne Fuqua is internationally recognized for her work on estrogen receptors in breast cancer. She was the first to discover constitutively active and hypersensitive estrogen receptor (ESR1) mutations in breast tumors, which has recently been confirmed by a number of investigators using next generation sequencing. It is estimated that approximately 20-40% of therapy-resistant metastatic breast tumors contain constitutively-active ESR1 mutations. She is thus a pioneer in this field.
Recently she also discovered that the androgen receptor (AR) was overexpressed in metastatic ER-positive tumors resistant to tamoxifen, and her preclinical studies have demonstrated that AR overexpression confers resistance to hormonal agents. Her work provided scientific rational for ongoing clinical trials of AR antagonists in ER-positive breast cancer.
Suzanne Fuqua is a translational scientist with many years' experience in molecular biology, functional genomics, precision medicine, steroid receptors, cell signaling and growth factor receptors.
Lynette Sholl (Molecular Diagnostics)
Dr. Sholl is an associate pathologist at Brigham and Women’s Hospital in Boston, Massachusetts and Associate Professor of Pathology at Harvard Medical School. She is board certified in anatomic pathology and molecular genetics pathology with an expertise in neoplastic and non-neoplastic lung diseases.
She completed her medical school training at Stanford University School of Medicine in Stanford, California; an internship in internal medicine at the Hospital of University of Pennsylvania; Anatomic Pathology residency and fellowship training at Brigham and Women’s Hospital; and the molecular genetics pathology fellowship at the Harvard teaching hospitals.
Dr. Sholl has been serving as an attending physician in general surgical pathology, pulmonary pathology, and molecular genetics pathology at BWH since 2009. She additionally serves as the Associate Director of the Center for Advanced Molecular Diagnostics and the Chief and fellowship director of the Thoracic Pathology Service.
Her research efforts focus on the molecular mechanisms of tumorigenesis and validation of novel molecular and immunohistochemical tests for genetic characterization of lung cancers in clinical practice.
Rulla Tamimi (Epidemiology)
Rulla Tamimi is a Professor of Population Health Sciences and Division Chief of Epidemiology in the department of Population Health Sciences at Weill Cornell Medicine. As the Associate Director for Population Science at the Sandra and Edward Meyer Cancer Center, she works closely with an interdisciplinary group of investigators to study cancer risk and survival with the goal of reducing morbidity and mortality in the New York City area.
Her research goal is to better understand breast cancer risk and prognosis by designing epidemiological studies that integrate biomarkers, imaging and lifestyle factors. Specifically, her research has focused on intermediate markers of breast cancer risk including mammographic density and benign breast diseases. As PI of multiple NIH-funded grants to understand risk factors for breast cancer, her group has identified a number of genetic, molecular and lifestyle predictors of breast cancer risk and survival. Many of these studies are based within the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII). She led research on breast cancer and served as PI of the Nurses’ Health Study, and Growing Up Today Study (GUTS) before starting at Weill Cornell Medicine.
Prof. Charles Lawrie is Director of the Oncology Research area of Biodonostia Institute, San Sebastián, Spain. An Ikerbasque Research Professor, Marie Curie Fellow, Fellow of Royal College of Pathologists (FRCPath), University Research lecturer of the University of Oxford and Visiting Professor of Shanghai University. He did his first degree and masters in Biochemistry (BA, MA (Oxon)) and doctoral degree (DPhil) at Trinity College, University of Oxford before setting up the lymphoid malignancy research group (LMRG) in the Nuffield Department of Clinical Laboratory Sciences (NDCLS), part of the Medical Sciences Division of the University of Oxford based at the John Radcliffe Hospital. He has published >110 scientific articles, books and book chapters and is a pioneer in the field of cancer liquid biopsies with the first description of miRNAs biomarkers in the blood of cancer patients. He serves on the editorial board of eleven journals and is associate editor of British Journal of Cancer (Nature) and Biochemistry and Biophysical Reports (Elsevier). He is the co-founder and CEO of Indicate Solutions S.L. (Spain), CSO (and co-founder) of Repvit UK Ltd and director and co-founder of Indicate Biotech (Shanghai).
Sara Lindstroem is an Associate Professor of Epidemiology at University of Washington (UW), the Institute for Public Health Genetics at UW, and the Public Health Sciences Division at Fred Hutchinson Cancer Research Center. Her research focuses on understanding the genetic contribution to diseases with an emphasis on cancer and related traits. By leveraging large-scale population-based studies, she studies how our genetics and environment affect disease risk. She leads multiple international efforts to study genetic risk factors for cancer and mammographic density, and she is also studying the genetics underlying a range of outcomes in people living with HIV.
Dr. Helen MacKay is a Medical Oncologist and Professor of Medicine at the University of Toronto. She is Head of the Division of Medical Oncology and Hematology at the Odette Cancer Centre at Sunnybrook Health Sciences Centre, and Senior Scientist at the Sunnybrook Research Institute. Dr. MacKay's clinical practice and research focus is on gynecological cancers. Her research involves collaborating with translational and basic scientists in the development and validation of novel therapeutic strategies. She is the current President of the Society of Gynecologic Oncology of Canada (GOC). She co-chairs the NCI (US), Ovarian Cancer Task Force. She is the past chair of the Ovarian Group and sits on the executive of the Gyne committee of the Canadian Cancer Trials Group (CCTG), and represents CCTG at the Gynecologic Cancer Intergroup. She is a past chair of both the Gynecologic Cancer Education and Scientific Committees for ASCO. With specific reference to uterine cancers, she is a member of the TRANSPORTEC group, and sits on the Corpus Committee of NRG, and was the co-chair of the NCI Endometrial Cancer Clinical Trials Planning Committee.
Adrian Marino-Enriquez is an Assistant Professor of Pathology at Brigham and Women's Hospital. His academic work is dedicated to sarcoma translational research, with an emphasis on therapeutic target discovery. Adrian's research aims to deepen the current understanding of sarcoma biology utilizing state-of-the-art experimental functional genomic techniques, building upon thoughtful morphologic and clinicopathological observation, to ultimately improve patient care and inform therapeutic development.
Massimiliano (Max) Mazzone graduated in Medical Biotechnology at the Medical School of the University of Torino, Italy, and then performed his PhD in Cell Science and Technologies at the Institute for Cancer Research of Torino, under the supervision of Prof. Comoglio. In November 2006, he moved to Belgium as an EMBO-awarded postdoctoral fellow in the lab of Prof. Peter Carmeliet, at the University of Leuven, Belgium. Since October 2009, he is heading the Lab of Tumor Inflammation and Angiogenesis, at the Center for Cancer Biology, part of VIB in Leuven, and, since 2017, he is Full Professor at the University of Leuven. From April 2019, Max was nominated Professor at the University of Torino where he is also visiting scientist at the Molecular Biotechnology Center. Max Mazzone has contributed to the field of oncology understanding the mechanisms of cancer metastasis and to vascular biology identifying a new endothelial cell phenotype, the "phalanx" cell, which takes part in the formation of aligned blood vessels in perfused tissues. Since end of 2009, he is independent group leader and his team is focusing in studying the response of inflammatory cells to hypoxic and metabolic conditions in order to restore blood flow and regulate favorably the immune response in conditions such as cancer and ischemic pathologies. From there, Max got other important national and international awards (the Lorini Award, the Belgian Royal Academy Prize, Giulia Colletta Award, EMBO awards, Chiara D’Onofrio Award, AstraZeneca Award, Burgen Award and others) and international recognitions (including 4 ERC grants: ERC Starting, ERC Proof-of-concept, and currently an ERC Consolidator, and a second ERC Proof-of-cocept). Max Mazzone was first EMBO Young Investigator and since 2021, EMBO Member. Until February 2022, Mazzone has authored 147 papers papers (of which 26 as senior author), with an average impact factor in first or senior corresponding author research papers of 15.48; more than 16000 citations; and an H-index of 53. He is member of the boards of several peer-reviewed journals (such as Cancer Research and Immunometabolism), he is reviewer for almost 20 journals, and he has been so far invited to speak in more than 120 international conferences (including GRC, Keystone, AACR, EMBO and FEBS meetings, Cell symposia, Cold Spring Harbor Conferences, ESMO, EACR, etc.) and in more than 80 institutional seminars. The translation and valorization of his work is proven by ongoing clinical trials, two spin-offs, a prospective study, numerous industrial collaborations (more than ten), drug screening programs, several (licensed) patents and the launch of two spinoff companies of which he is the scientific founder, Oncurious and Montis Biosciences.
Professor Tim Price is Medical Oncologist and Head of Clinical Cancer Research at The Queen Elizabeth Hospital, Adelaide South Australia. He is a Professor at the University of Adelaide, and visiting Professor Antwerp University Belgium and University of Sydney, Sydney Australia. In addition, Tim is Medical Director of the Cancer Program (Central Adelaide Local Health Network), Laboratory Head of the Solid Cancer Group Bazil Hetzel Institute, Board Director for the Australasian Gastrointestinal Trials Group (AGITG) and the Clinical Oncology Society of Australia. His major clinical and research focus is on Gastrointestinal cancers, Neuroendocrine malignancy and Phase I clinical trials.
Dr. Salma Shariff-Marco is a social and behavioral scientist with a research portfolio focused on understanding the role of structural and social determinants of health in shaping and perpetuating health disparities. One main area of focus is on place and health, evaluating how neighborhood characteristics (e.g., social, built, and physical environment attributes) and geographic variation may shape cancer-related health behaviors and outcomes across the cancer continuum. In addition, her research includes efforts to better characterize neighborhoods for population health studies (neighborhood archetypes, virtual audits with Google Street View). Another area of research includes understanding how factors related to social status (race/ethnicity, socioeconomic status, and immigration) impact health disparities, particularly applying an intersectional lens. Dr. Shariff-Marco is also a co-Investigator of the Greater Bay Area Cancer Registry, a part of the California Cancer Registry and the NCI Surveillance Epidemiology End Results (SEER) Program.
Takatsugu Ishimoto is a Group Leader (Gastrointestinal Cancer Biology) at International Research Center of Medical Sciences (IRCMS) in Kumamoto University, Kumamoto, Japan. He received an M.D. from Kumamoto University School of Medicine in 2001. After completing the surgical residency-fellowship program (2001-2006), he received a Ph.D. degree at Kumamoto University Graduate School of Medical Sciences in 2009. He then finished a post-doctoral fellowship in Prof. Hideyuki Saya’s Lab at Keio University Graduate School of Medicine (2009-2011). After that, he was promoted to an Assistant Professor and have been engaged in surgical clinical practice and cancer research at Kumamoto University Hospital (2011-2014), and then also worked as a Visiting Assistant Professor in Prof. Patrick Tan’s Lab at Duke-NUS Medical School, Singapore (2014-2016). His main research interests focus on are tumor microenvironment, cancer metabolism, cancer stem cell biology in gastrointestinal cancers including pancreatic cancer and HCC.
Rob Williams is Chief Drug Development Scientist at Cancer Research UK’s Centre for Drug Development. At CRUK Rob has overseen the delivery of over 25 drug candidates into first-in-human clinical trials including cell therapies, vaccines, antibodies and small molecules. Rob has a PhD in pharmacology and previously held scientific leadership positions in metabolic and inflammatory diseases with Glaxo and Rhone-Poulenc Rorer. He has also worked in biotech and during his time at Prolifix, led on the pre-clinical characterisation and early development of Belinostat, now an approved medicine for the treatment of peripheral T-cell lymphoma. Rob acts as a scientific advisor for a number of both non-commercial and commercial research organisations, lectures in drug development on several MSc courses, is a trustee of the PTEN research foundation and co-founded Duke Street Bio, an Immuno-oncology-focused drug discovery company.
Jun Yang is an Assistant Member in the Department of Surgery at St Jude Children’s Research Hospital. He obtained his medical degree (MBBS) in Qingdao Medical College, and Master in Medicine at The National Institute for Biological and Pharmaceutical Products in Beijing, where he cloned the genotype 4 of hepatitis E virus and a series of novel strains of TT virus. Jun Yang obtained his PhD degree under the supervision of Dr. Margaret Ashcroft, in the Department of Cancer Therapeutics at the Institute of Cancer Research in UK, where he studied the regulation of hypoxia-inducible factor 1. Jun Yang joined Dr. Adrian Harris’s laboratory as a postdoctoral fellow at Oxford University, where he studied hypoxia-mediated epigenetic regulation through histone demethylases. Jun Yang then joined St. Jude Children’s Research Hospital in Memphis, as a postdoctoral research fellow, to continue studying the functions of histone demethylases in pediatric cancers and develop novel anticancer therapies, where he was promoted to be a faculty member in Department of Surgery. Jun Yang is a Research Scholar of American Cancer Society.
His main research interests focus on epigenetic mechanisms in oncogenesis by using cutting-edge technologies (i.e., scRNA-seq, spatiotranscriptomics, ChIP-seq/Cut&Tag, genome-wide CRISPR editing), generation of transgenic mouse models to understand the mechanism of tumor initiation and progression, design translational therapies using high-risk pediatric cancer models, and drug development by using medicinal chemistry and biophysical approaches.
Timothy A. Yap
Dr. Timothy Yap is a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center. He is an Associate Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of Thoracic/Head and Neck Medical Oncology. Dr. Yap is the Medical Director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also the Associate Director of Translational Research in the Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes. Prior to his current position, Dr. Yap was a Consultant Medical Oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research BRC Clinician Scientist at The Institute of Cancer Research, London, UK.
Dr. Yap’s main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. His main interests include the targeting of the DNA damage response (DDR) with novel therapeutics, such as PARP, ATR, WEE1, DNA-PK, RAD51, POLQ, PK-MYT1 and USP1 inhibitors, as well as the development of novel immunotherapeutics.
Veera Panova is a postdoctoral scientist at the Weatherall Institute of Molecular Medicine (WIMM). She did her first degree and Master of Research degree in London and then completed her PhD at the Laboratory of Molecular Biology in Cambridge.